相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
Frank Kolbinger et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
Kenneth B. Gordon et al.
JAMA DERMATOLOGY (2022)
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Vishnu Eshwar et al.
PHARMACEUTICALS (2022)
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B Gordon et al.
LANCET (2021)
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
Kim A Papp et al.
LANCET (2021)
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
Sophie Glatt et al.
JAMA DERMATOLOGY (2021)
Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis
Kyle Fahrbach et al.
DERMATOLOGY AND THERAPY (2021)
Dual inhibition of IL-17A and IL-17F in psoriatic disease
Helena Iznardo et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2021)
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial
Rachel G. Casseres et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study
Maria Antonietta Barbieri et al.
JOURNAL OF CLINICAL MEDICINE (2020)
The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment
Lisa Lynn ten Bergen et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2020)
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
Ralph Adams et al.
FRONTIERS IN IMMUNOLOGY (2020)
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Taoming Liu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study
Karel Pavelka et al.
ACR OPEN RHEUMATOLOGY (2020)
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
Laura M. Sawyer et al.
PLOS ONE (2019)
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Fan Bai et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
IL-17 receptor-based signaling and implications for disease
Xiaoxia Li et al.
NATURE IMMUNOLOGY (2019)
Review of IL-17 inhibitors for psoriasis
Mina Amin et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials
Lian Cui et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis
Kristian Reich et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Nicolo Costantino Brembilla et al.
FRONTIERS IN IMMUNOLOGY (2018)
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis
Frank Kolbinger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents
Lukasz Matusiak et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Affibody Molecules in Biotechnological and Medical Applications
Stefan Stahl et al.
TRENDS IN BIOTECHNOLOGY (2017)
The global state of psoriasis disease epidemiology: a workshop report
C. E. M. Griffiths et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Affibody molecules as engineered protein drugs
Fredrik Y. Frejd et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases
Michela Silacci et al.
MABS (2016)
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Jens Sorensen et al.
THERANOSTICS (2016)
Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa
Alex Anstey
BRITISH JOURNAL OF DERMATOLOGY (2015)
Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy
Erik Letko et al.
OPHTHALMOLOGY (2015)
Early Implementation of QbD in Biopharmaceutical Development: A Practical Example
Jesus Zurdo et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial
B. Zhu et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
The expression and significance of T helper cell subsets and regulatory T cells CD4+CD25+ in peripheral blood of patients with human leukocyte antigen B27-positive acute anterior uveitis
Wenjun Zou et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2014)
Elevated Serum Levels of Interleukin-17A in Uveitis Patients
Shayma Jawad et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2013)
Crystal structures of interleukin 17A and its complex with IL-17 receptor A
Shenping Liu et al.
NATURE COMMUNICATIONS (2013)
Psoriasis Severity and the Prevalence of Major Medical Comorbidity A Population-Based Study
Howa Yeung et al.
JAMA DERMATOLOGY (2013)
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
J. Lofblom et al.
FEBS LETTERS (2010)
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
C. Johansen et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Antonella Di Cesare et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Selection and characterization of affibody ligands binding to Alzheimer amyloid β peptides
Caroline Gronwall et al.
JOURNAL OF BIOTECHNOLOGY (2007)
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent
Mark S. Dennis et al.
CANCER RESEARCH (2007)
Formatted anti-tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis
Ken Coppieters et al.
ARTHRITIS AND RHEUMATISM (2006)
Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis
A Wunder et al.
JOURNAL OF IMMUNOLOGY (2003)
分享论文
